post-template-default,single,single-post,postid-1420,single-format-standard,strata-core-1.1.1,strata-child-theme-ver-1.0.0,strata-theme-ver-3.4,ajax_fade,page_not_loaded,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

Seqirus opens new corporate office in the Thames Valley

13:07 07 December in Sectors

Paul Britton, Chief Executive of Thames Valley Chamber of Commerce, attended the formal opening. “Thames Valley Chamber were delighted to work with UK Trade & Investment to support CSL in making the decision to base Seqirus’ operational hub in the UK, and we will continue to work with the company as they settle in and grow as a business.”

Attending the formal office opening today, Home Secretary and Member of Parliament for Maidenhead, Mrs Theresa May MP said, “It is a pleasure to open the Seqirus office here in Maidenhead. They join a significant cluster of Life Sciences and Healthcare businesses that have chosen the town as their base, drawn here by a highly skilled workforce and specialist talent pool, connectivity to London Heathrow, proximity to the world’s leading research institutions (University of Oxford) and some of the country’s best quality of living. It is an endorsement too of the collective efforts of UKTI and local partners in supporting the business in its decision to invest in Maidenhead, the Thames Valley and the UK.

The Leader of the Royal Borough of Windsor and Maidenhead, Councillor David Burbage who was also attending, commented: “We welcome Gordon, his senior management team and all the Seqirus staff to Maidenhead. It’s a significant investment in and endorsement of the continued success of the Royal Borough as a destination of choice many of the Thames Valley’s most recent investors. We look forward to working with the business more closely; welcoming their staff into our community and supporting the expansion of their global business operations from the office here in Maidenhead.”

The Minister for Life Sciences, George Freeman MP, was unable to attend the opening but provided a welcoming statement: “This news that CSL, one of the world’s leading biopharmaceutical companies, has chosen the UK as the new corporate office location for this major new business (Seqirus) is a strong endorsement of the UK as a global life science cluster. This major investment in the strategically important vaccines sector is great news for UK leadership in vaccine science and public health. The decision also underlines the attractiveness of the UK as a business and export base for global life sciences companies.”

About Seqirus
Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now the second largest influenza vaccine provider in the world. With extensive research and production expertise and manufacturing plants in the US, Australia, UK and Germany, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 2,000 employees, significant manufacturing capacity, and a commercial presence in 20 countries.